guest ::
| Home > Publications database > PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. > print |
| Home > Publications database > PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. > print |
| 001 | 274211 | ||
| 005 | 20240229154929.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-023-06185-5 |2 doi |
| 024 | 7 | _ | |a pmid:36905411 |2 pmid |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 0340-6997 |2 ISSN |
| 024 | 7 | _ | |a 1432-105X |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 024 | 7 | _ | |a altmetric:143798646 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-00497 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Solomonidou, Nantia |b 0 |
| 245 | _ | _ | |a PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2023 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1686641822_12253 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2023 Jul;50(8):2529-2536 |
| 520 | _ | _ | |a The purpose of this retrospective, multicenter study was to assess efficacy of PSMA-PET/CT-guided salvage radiotherapy (sRT) in patients with recurrent or persistent PSA after primary surgery and PSA levels < 0.2 ng/ml.The study included patients from a pooled cohort (n = 1223) of 11 centers from 6 countries. Patients with PSA levels > 0.2 ng/ml prior to sRT or without sRT to the prostatic fossa were excluded. The primary study endpoint was biochemical recurrence-free survival (BRFS) and BR was defined as PSA nadir after sRT + 0.2 ng/ml. Cox regression analysis was performed to assess the impact of clinical parameters on BRFS. Recurrence patterns after sRT were analyzed.The final cohort consisted of 273 patients; 78/273 (28.6%) and 48/273 (17.6%) patients had local or nodal recurrence on PET/CT. The most frequently applied sRT dose to the prostatic fossa was 66-70 Gy (n = 143/273, 52.4%). SRT to pelvic lymphatics was delivered in 87/273 (31.9%) patients and androgen deprivation therapy was given to 36/273 (13.2%) patients. After a median follow-up time of 31.1 months (IQR: 20-44), 60/273 (22%) patients had biochemical recurrence. The 2- and 3-year BRFS was 90.1% and 79.2%, respectively. The presence of seminal vesicle invasion in surgery (p = 0.019) and local recurrences in PET/CT (p = 0.039) had a significant impact on BR in multivariate analysis. In 16 patients, information on recurrence patterns on PSMA-PET/CT after sRT was available and one had recurrent disease inside the RT field.This multicenter analysis suggests that implementation of PSMA-PET/CT imaging for sRT guidance might be of benefit for patients with very low PSA levels after surgery due to promising BRFS rates and a low number of relapses within the sRT field. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a PSMA-PET |2 Other |
| 650 | _ | 7 | |a Prostate cancer |2 Other |
| 650 | _ | 7 | |a Prostate-specific antigen |2 Other |
| 650 | _ | 7 | |a Salvage radiotherapy |2 Other |
| 700 | 1 | _ | |a Germanou, Daphnie |b 1 |
| 700 | 1 | _ | |a Strouthos, Iosif |b 2 |
| 700 | 1 | _ | |a Karagiannis, Efstratios |b 3 |
| 700 | 1 | _ | |a Farolfi, Andrea |b 4 |
| 700 | 1 | _ | |a Koerber, Stefan A |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Debus, Jürgen |0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |b 6 |u dkfz |
| 700 | 1 | _ | |a Peeken, Jan C |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Vogel, Marco E |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Vrachimis, Alexis |b 9 |
| 700 | 1 | _ | |a Spohn, Simon K B |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Shelan, Mohamed |b 11 |
| 700 | 1 | _ | |a Aebersold, Daniel |b 12 |
| 700 | 1 | _ | |a Grosu, Anca-Ligia |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Ceci, Francesco |b 14 |
| 700 | 1 | _ | |a Kroeze, Stephanie G C |b 15 |
| 700 | 1 | _ | |a Guckenberger, Matthias |b 16 |
| 700 | 1 | _ | |a Fanti, Stefano |b 17 |
| 700 | 1 | _ | |a Belka, Claus |b 18 |
| 700 | 1 | _ | |a Hruby, George |b 19 |
| 700 | 1 | _ | |a Scharl, S. |b 20 |
| 700 | 1 | _ | |a Wiegel, Thomas |b 21 |
| 700 | 1 | _ | |a Bartenstein, Peter |b 22 |
| 700 | 1 | _ | |a Henkenberens, Christoph |b 23 |
| 700 | 1 | _ | |a Emmett, Louise |b 24 |
| 700 | 1 | _ | |a Schmidt-Hegemann, Nina Sophie |b 25 |
| 700 | 1 | _ | |a Ferentinos, Konstantinos |b 26 |
| 700 | 1 | _ | |a Zamboglou, Constantinos |0 0000-0002-7849-7550 |b 27 |
| 773 | _ | _ | |a 10.1007/s00259-023-06185-5 |0 PERI:(DE-600)2098375-X |n 8 |p 2529-2536 |t European journal of nuclear medicine and molecular imaging |v 50 |y 2023 |x 1619-7070 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:274211 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 0000-0002-7849-7550 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2022-11-23 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2022-11-23 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-23 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-23 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-23 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2023-08-23 |
| 920 | 1 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)MU01-20160331 |k MU01 |l DKTK MU LMU zentral |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)FR01-20160331 |k FR01 |l DKTK FR zentral |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E050-20160331 |
| 980 | _ | _ | |a I:(DE-He78)MU01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)FR01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|